Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic and Nutritional Complications Clear all
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 14, 2026, 7:47 AM EDT
Not listed Not applicable Interventional

Comparison of Glucovance to Insulin for Diabetes During Pregnancy

NCT00371306
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes, Pregnancy
Interventions
Insulin versus glucovance (glyburide/metformin)
Drug
Lead sponsor
Regional Obstetrical Consultants
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional

Bicarbonate Administration in Kidney Transplant Recipients

NCT03428464
View directory record Official record
Conditions
Kidney Transplant; Complications, Metabolic Acidosis
Interventions
Sodium Bicarbonate, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

NCT02545049
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
173
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 14, 2026, 7:47 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 14, 2026, 7:47 AM EDT
Completed No phase listed Observational

Autoimmunity in Neurologic Complications of Celiac Disease

NCT00692861
View directory record Official record
Conditions
Ataxia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 14, 2026, 7:47 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

NCT07290673
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
FoundationDRS Solo, Standard of Care
Other
Lead sponsor
Samaritan Biologics
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Phase 3 Interventional Results available

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT00680017
View directory record Official record
Conditions
Dyslipidemia, Kidney Disease
Interventions
ABT-335 plus rosuvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
102
States / cities
Birmingham, Alabama • Huntsville, Alabama • Madison, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 14, 2026, 7:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Diabetes in Young Turner Syndrome Patients

NCT02160717
View directory record Official record
Conditions
Turner Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 14, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional Results available

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

NCT00837824
View directory record Official record
Conditions
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions
Fabrazyme (agalsidase beta)
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 14, 2026, 7:47 AM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device

NCT05368623
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
Interventions
Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
Diagnostic Test · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional Results available

Metabolic Syndrome in PCOS: Precursors and Interventions

NCT00442689
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions
flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 14, 2026, 7:47 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 7:47 AM EDT
Completed No phase listed Observational

Studies of States With Resistance to Vitamin D and Parathyroid Hormone

NCT00001242
View directory record Official record
Conditions
Hypocalcemia, Pseudohypoparathyroidism, Osteomalacia, Rickets, Pseudopseudohpoparathyroidism
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 14, 2026, 7:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy

NCT06911372
View directory record Official record
Conditions
Gestational Diabetes Mellitus (GDM), Postpartum Women, Uncomplicated Pregnancy
Interventions
Intradermal Microdialysis, Brain Blood Flow Tests, Local Heating
Drug · Other
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 14, 2026, 7:47 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.

NCT02344329
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetes
Interventions
Topical wound dressing, Human Amnion Allograft, usual wound care
Device · Biological · Other
Lead sponsor
University of North Dakota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postpartum Weight Retention

NCT02867631
View directory record Official record
Conditions
Obesity, Hypertension, Depression
Interventions
6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Not applicable Interventional

Avoiding Diabetes After Pregnancy Trial

NCT01923350
View directory record Official record
Conditions
Weight Reduction
Interventions
Weight Reduction Intervention, Weight Reduction Control Arm, Tested for diabetes, Not tested for diabetes
Behavioral
Lead sponsor
Social & Scientific Systems Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 14, 2026, 7:47 AM EDT
Completed No phase listed Observational

Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women

NCT00017797
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2006 · Synced Oct 14, 2026, 7:47 AM EDT
Completed Phase 2 Interventional

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

NCT00312780
View directory record Official record
Conditions
Albuminuria, Diabetic Nephropathy
Interventions
XL784
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 14, 2026, 7:47 AM EDT